Evidence map›Paper›PMID 36480167›Full record

ArticleCancer research2023

Elevated Methionine Flux Drives Pyroptosis Evasion in Persister Cancer Cells.

Asmaa El-Kenawi, Anders Berglund, Veronica Estrella, Yonghong Zhang, Min Liu, Ryan M Putney, Sean J Yoder, Joseph Johnson, Joel Brown, Robert Gatenby

Open access · hybridAbstract read
In one paragraph

Article in Cancer research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 33 citations in OpenAlex.

  1. Regulated cell death programs shaping cancer therapy.Cellular oncology (Dordrecht, Netherlands) · 2026
    Review
  2. Review
  3. Pyroptosis: Turning Up the Heat on Cancer.Annual review of immunology · 2026
    Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Asmaa El-KenawiDepartment of Radiation Oncology, H. Lee Moffitt Cancer Center, Tampa, Florida.ORCID 0000-0003-2039-2825
Anders BerglundDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, Florida.ORCID 0000-0002-0393-3530
Veronica EstrellaCancer Biology and Evolution Program, H. Lee Moffitt Cancer Center, Tampa, Florida.ORCID 0000-0001-9943-544X
Yonghong ZhangBiostatistics and Bioinformatics Shared Resource, H. Lee Moffitt Cancer Center, Tampa, Florida.ORCID 0000-0001-9565-7563
Min LiuProteomics and Metabolomics Core Facility, H. Lee Moffitt Cancer Center, Tampa, Florida.ORCID 0000-0003-2138-8000
Ryan M PutneyDepartment of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center, Tampa, Florida.ORCID 0000-0002-0468-736X
Sean J YoderMolecular Genomics Core Facility, H. Lee Moffitt Cancer Center, Tampa, Florida.ORCID 0000-0002-3120-3279
Joseph JohnsonAnalytic Microscopy Core Facility, H. Lee Moffitt Cancer Center, Tampa, Florida.ORCID 0000-0001-8574-6909
Joel BrownCancer Biology and Evolution Program, H. Lee Moffitt Cancer Center, Tampa, Florida.ORCID 0000-0002-0958-9494
Robert GatenbyCancer Biology and Evolution Program, H. Lee Moffitt Cancer Center, Tampa, Florida.ORCID 0000-0002-1621-1510
Moffitt Cancer Center · US

Funding

TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
"Research Supplement to Promote Diversity in Health-Related Research", as part of Moffitt PS-OC, "Cancer as a Complex adaptive System"U54CA193489 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI ANDERSON, ALEXANDER ROBERTSON ALLAN, GATENBY, ROBERT A · 2015 to 2020
$12.5M
Eco-Evolutionary dynamics of NSCLC to immunotherapy: Response and ResistanceU01CA232382 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI ANDERSON, ALEXANDER ROBERTSON ALLAN, ANTONIA, SCOTT J. · 2018 to 2022
$3.3M
NCI NIH HHS P30 CA076292NCI NIH HHS U01 CA232382NCI NIH HHS U54 CA193489
6 · The paper itself

Abstract

Induction of cell death represents a primary goal of most anticancer treatments. Despite the efficacy of such approaches, a small population of "persisters" develop evasion strategies to therapy-induced cell death. While previous studies have identified mechanisms of resistance to apoptosis, the mechanisms by which persisters dampen other forms of cell death, such as pyroptosis, remain to be elucidated. Pyroptosis is a form of inflammatory cell death that involves formation of membrane pores, ion gradient imbalance, water inflow, and membrane rupture. Herein, we investigate mechanisms by which cancer persisters resist pyroptosis, survive, then proliferate in the presence of tyrosine kinase inhibitors (TKI). Lung, prostate, and esophageal cancer persister cells remaining after treatments exhibited several hallmarks indicative of pyroptosis resistance. The inflammatory attributes of persisters included chronic activation of inflammasome, STING, and type I interferons. Comprehensive metabolomic characterization uncovered that TKI-induced pyroptotic persisters display high methionine consumption and excessive taurine production. Elevated methionine flux or exogenous taurine preserved plasma membrane integrity via osmolyte-mediated effects. Increased dependency on methionine flux decreased the level of one carbon metabolism intermediate S-(5'-adenosyl)-L-homocysteine, a determinant of cell methylation capacity. The consequent increase in methylation potential induced DNA hypermethylation of genes regulating metal ion balance and intrinsic immune response. This enabled thwarting TKI resistance by using the hypomethylating agent decitabine. In summary, the evolution of resistance to pyroptosis can occur via a stepwise process of physical acclimation and epigenetic changes without existing or recurrent mutations. SIGNIFICANCE: Methionine enables cancer cells to persist by evading pyroptotic osmotic lysis, which leads to genome-wide hypermethylation that allows persisters to gain proliferative advantages.

Indexed as

NeoplasmsPyroptosisApoptosisCell DeathHumansInflammasomesMethionineRacemethionineInflammasomesMethionineRacemethionine

Identifiers

PMID36480167
PMCPMC9978888
OpenAlexW4310962695

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.